Pricing Log in Create free account
Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue
+13.4%
EPS
+241.5%
Free cash flow
+240.7%
Total debt
+51.6%

Quarter to September 2026, against a year earlier

28.21 0.06 +0.21%
Market cap
$5.6B
P/E
7.6×
Fwd P/E
9.5×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Indivior Pharmaceuticals Inc. (SUPN) EV/EBITDA

Alert me on EV/EBITDA

As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a EV/EBITDA of 7.0×. Over the past ten years it has ranged from 0.0× (December 2024) to 29.6× (June 2025); the current reading is higher than 54% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 12.2× and below the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 16.3× (34.77%)
FY2024 25.1× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 7.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.9× (94.83%)
FY2017 17.4× 18.27%
FY2016 14.7× 165.82%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 8.6× (27.55%)
Jun 2026 11.8× 0.93%
Mar 2026 11.7× (28.19%)
Dec 2025 16.3× 41.91%
43 more quarters

Against its own ten years

Low 0.0× High 29.6×
Ten-year median 5.7×
Current reading's percentile 54

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
LNTH Lantheus Holdings, Inc. compare 16.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on SUPN